Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has received an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.75.

Several brokerages have recently issued reports on DRNA. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target (up from $6.00) on shares of Dicerna Pharmaceuticals in a research report on Friday. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Chardan Capital reaffirmed a “hold” rating on shares of Dicerna Pharmaceuticals in a research report on Monday, August 14th. Finally, Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC lifted its stake in shares of Dicerna Pharmaceuticals by 101.0% in the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock valued at $2,435,000 after buying an additional 385,992 shares during the period. Palo Alto Investors LLC lifted its stake in shares of Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after buying an additional 19,394 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock valued at $1,423,000 after buying an additional 9,818 shares during the period. Vanguard Group Inc. lifted its stake in shares of Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after buying an additional 14,517 shares during the period. Finally, UBS Group AG lifted its stake in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the period. Institutional investors and hedge funds own 55.94% of the company’s stock.

Shares of Dicerna Pharmaceuticals (DRNA) traded up $2.14 during trading hours on Friday, hitting $7.78. The stock had a trading volume of 920,280 shares, compared to its average volume of 220,188.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 210.01%. The business’s revenue was up 192.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.68) earnings per share. equities research analysts predict that Dicerna Pharmaceuticals will post -3.13 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Dicerna Pharmaceuticals, Inc. (DRNA) PT at $6.08” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/brokerages-set-dicerna-pharmaceuticals-inc-drna-pt-at-6-08/1676309.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.